Levothyroxine Supplementation for Heart Transplant Recipients
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
Eligibility criteria
Qualifiers
Participants must be listed for heart transplantation
Age ≥18 years
Ability to understand and the willingness to sign a written informed consent document.
Disqualifiers
Patients with pre-existing thyroid related condition including hypothyroidism, hyperthyroidism and malignancy
Patients with a known allergy or intolerance to levothyroxine
Patients participating in another study evaluating an investigational drug within the past 30 days.
Trial design
Treatments tested in this trial
- Levothyroxine
- Normal saline
Treatment groups
97 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov